The International Generic and Biosimilar medicines Association (IGBA) welcomes the adoption of the WHO Pandemic Agreement at the 78th World Health Assembly in May 2025. This landmark accord represents a critical step toward strengthening global preparedness and ensuring equitable access to essential health products in future pandemics.
The International Generic and Biosimilar medicines Association (IGBA), being the global voice of generic and biosimilar medicines industries, calls for G7 countries to consider health and access to health as a priority in its upcoming discussions, to be held in Alberta, Canada.
The International Generic and Biosimilar medicines Association (IGBA) commends the General Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) for its adoption of a new topic focused on the harmonisation of "Framework for Determining Utility of Comparative Efficacy Studies in Biosimilar Development Programs."
- IGBA Statement on trade barriers and their impact on healthcare systems and patients’ health (March 2025)
- Harmonising Bioequivalence: Advancing Global Access to Generic Medicines (February 2025)
- IGBA releases first global Intellectual Property and Competition Report (February 2025)
- Joint Industry Statement for WHO's Executive Board Meeting 156 (February 2025)
